英国国家卫生与临床优化研究所的成本效益范围：是否应该降低？ - Suppr

NICE's cost-effectiveness range: should it be lowered?

作者信息

Raftery J P

机构信息

University of Southampton, Southampton, UK,

出版信息

Pharmacoeconomics. 2014 Jul;32(7):613-5. doi: 10.1007/s40273-014-0158-6.

DOI:10.1007/s40273-014-0158-6

PMID:24811892

Abstract

摘要

相似文献

NICE's cost-effectiveness range: should it be lowered?

Pharmacoeconomics. 2014 Jul;32(7):613-5. doi: 10.1007/s40273-014-0158-6.

NICE's cost effectiveness threshold.

BMJ. 2007 Aug 25;335(7616):358-9. doi: 10.1136/bmj.39308.560069.BE.

Some inconsistencies in NICE's consideration of social values.

Pharmacoeconomics. 2014 Nov;32(11):1043-53. doi: 10.1007/s40273-014-0204-4.

Crossing the line: NICE's value for money threshold.

BMJ. 2016 Mar 9;352:i1336. doi: 10.1136/bmj.i1336.

Should NICE's threshold range for cost per QALY be raised? No.

BMJ. 2009 Jan 26;338:b185. doi: 10.1136/bmj.b185.

Should NICE's threshold range for cost per QALY be raised? Yes.

BMJ. 2009 Jan 26;338:b181. doi: 10.1136/bmj.b181.

Review of NICE's recommendations, 1999-2005.

BMJ. 2006 May 27;332(7552):1266-8. doi: 10.1136/bmj.332.7552.1266.

Protest over end of NICE's project on safe staffing.

Nurs Stand. 2015 Jun 24;29(43):9. doi: 10.7748/ns.29.43.9.s6.

Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?

Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):239-242. doi: 10.1080/14737167.2017.1330152. Epub 2017 May 23.

Interpretation of cost-effectiveness analyses.

J Gen Intern Med. 1998 Oct;13(10):716-7. doi: 10.1046/j.1525-1497.1998.00211.x.

引用本文的文献

The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS.

Pharmacoeconomics. 2022 Feb;40(2):233-239. doi: 10.1007/s40273-021-01090-x. Epub 2021 Oct 26.

Impact of a Global Pandemic on Health Technology Assessment.

Appl Health Econ Health Policy. 2020 Jun;18(3):339-343. doi: 10.1007/s40258-020-00590-9.

Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.

Pharmacoeconomics. 2020 Jul;38(7):665-681. doi: 10.1007/s40273-020-00907-5.

Estimating Social Variation in the Health Effects of Changes in Health Care Expenditure.

Med Decis Making. 2020 Feb;40(2):170-182. doi: 10.1177/0272989X20904360. Epub 2020 Feb 15.

The marginal benefits of healthcare spending in the Netherlands: Estimating cost-effectiveness thresholds using a translog production function.

Health Econ. 2019 Nov;28(11):1331-1344. doi: 10.1002/hec.3946. Epub 2019 Aug 30.

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.

Front Public Health. 2018 Dec 5;6:328. doi: 10.3389/fpubh.2018.00328. eCollection 2018.

Cognitive aids for people with early stage dementia versus treatment as usual (Dementia Early Stage Cognitive Aids New Trial (DESCANT)): study protocol for a randomised controlled trial.

Trials. 2018 Oct 10;19(1):546. doi: 10.1186/s13063-018-2933-8.

Improving the effectiveness of psychological interventions for depression and anxiety in the cardiac rehabilitation pathway using group-based metacognitive therapy (PATHWAY Group MCT): study protocol for a randomised controlled trial.

Trials. 2018 Apr 3;19(1):215. doi: 10.1186/s13063-018-2593-8.

Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Pharmacoeconomics. 2018 May;36(5):509-522. doi: 10.1007/s40273-017-0606-1.

Ethical Hurdles in the Prioritization of Oncology Care.

Appl Health Econ Health Policy. 2017 Apr;15(2):119-126. doi: 10.1007/s40258-016-0288-4.

本文引用的文献

The Influence of Cost-Effectiveness and Other Factors on Nice Decisions.

Health Econ. 2015 Oct;24(10):1256-1271. doi: 10.1002/hec.3086. Epub 2014 Sep 23.

Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice?

Pharmacoeconomics. 2014 Apr;32(4):315-8. doi: 10.1007/s40273-014-0146-x.

Can the real opportunity cost stand up: displaced services, the straw man outside the room.

Pharmacoeconomics. 2014 Apr;32(4):319-25. doi: 10.1007/s40273-014-0140-3.

Application of patient-reported outcome measures (PROMs) data to estimate cost-effectiveness of hernia surgery in England.

J R Soc Med. 2013 Jul;106(7):278-87. doi: 10.1177/0141076813489679. Epub 2013 May 28.

Using patient-reported outcome measures to estimate cost-effectiveness of hip replacements in English hospitals.

J R Soc Med. 2013 Aug;106(8):323-31. doi: 10.1177/0141076813489678. Epub 2013 May 28.

NICE's end of life decision making scheme: impact on population health.

BMJ. 2013 Mar 21;346:f1363. doi: 10.1136/bmj.f1363.

Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set.

BMJ Open. 2012 Jan 30;2(1):e000332. doi: 10.1136/bmjopen-2011-000332. Print 2012.

Comparing costs and outcomes across programmes of health care.

Health Econ. 2012 Mar;21(3):316-37. doi: 10.1002/hec.1716. Epub 2011 Feb 14.

Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.

Health Technol Assess. 2010 May;14(27):1-162. doi: 10.3310/hta14270.

Multiple sclerosis risk sharing scheme: a costly failure.

BMJ. 2010 Jun 3;340:c1672. doi: 10.1136/bmj.c1672.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

NICE's cost-effectiveness range: should it be lowered?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献